Fw: FDA - MedWatch - Viagra (sildenafil citrate), Levitra (vardenafil HCL), Cialis (tadalafil) - Reports Of Sudden Decreases Or Loss Of Hearing Following Use Of PDE5 Inhibitors

MedWatch - The FDA Safety Information and Adverse Event Reporting Program
FDA informed healthcare professionals of reports of sudden decreases or loss of hearing following the use of PDE5 inhibitors, Viagra, Levitra, Cialis for the treatment of erectile dysfunction and Revatio for the treatment of pulmonary arterial hypertension. In some cases, the sudden hearing loss was accompanied by tinnitus and dizziness. Medical follow-up on these reports was often limited which makes it difficult to determine if the loss of hearing was related to the use of one of the drugs, an underlying medical condition or other risk factors for hearing
loss, a combination of these factors or other factors. The PRECAUTION and updated Adverse Reactions Sections of the approved product labeling for Viagra, Levitra, and Cialis were revised. FDA is working with the manufacturer to revise the labeling for Revatio.Read the complete MedWatch 2007 Safety Summary including a link to the
Drug Information Page and revised prescribing information for Viagra,
Levitra, and Cialis regarding this issue at:
http://www.fda.gov/medwatch/safety/2007/safety07.htm#PDE5